Today: December 12, 2017, 4:57 pm
  
Health

Singapore eDevelopment Subsidiary Initiates Research on New Universal Therapeutic Drug Platform

Singapore eDevelopment Subsidiary Initiates Research on New Universal Therapeutic Drug Platform
PR-Inside.com: 2017-05-22 13:40:15
- Nobel Prize nominee Daryl Thompson to lead research, conducted by Global BioLife Inc., supported by Charles River Laboratories

- Six month target for validating lab data, twelve month target for completion of platform

SINGAPORE, May 22, 2017 - (ACN Newswire) - Singapore eDevelopment Ltd ("SeD"), through subsidiary Global BioLife Inc. ("Global BioLife"), has initiated advanced research on a new universal therapeutic drug platform known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee Mr Daryl Thompson.


SGX-listed SeD (SP:SGE) said Mr Thompson would leverage his expertise in organic and carbohydrate chemistry and the use of pandemic technology in combating the Ebola virus in the development of Linebacker. Unlike traditional approaches to curing individual diseases with specific drugs, the Linebacker platform seeks a breakthrough option for multiple diseases to be cured. It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria.

Mr Thompson will lead the research, to be conducted by Global BioLife, in his capacity as Director of Scientific Initiatives. Global BioLife is an 80%-held subsidiary of SeD's wholly-owned subsidiary, Global BioMedical Inc. The remaining stake in Global BioLife is held in equal proportions by Mr Thompson's GRDG Sciences LLC and ASX-listed Holista CollTech Limited.

Mr Thompson was nominated for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola. He has used his expertise to initiate research regarding universal therapeutics to cure the world's deadliest diseases. Mr Scott Truesdell, Research Coordinator and Special Projects Leader at Global BioLife, will execute the research on the Linebacker platform.

Global BioLife has engaged NYSE-listed Charles River Laboratories International, Inc., which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Mr Thompson said, "We expect to obtain validating laboratory data from the universal therapeutic drug platform within the first six months and are targeting for the platform itself to be completed within twelve months. We have a unique patented technology and are already getting interest from Big Pharma players and venture capitalists. This interest will rise as the validating data becomes available."

"Global BioLife recognizes the need for affordable cures to emerging pandemics and we will leverage the team's deep expertise to develop this new universal therapeutic drug platform," said Dr Tang Peihong, Global BioLife Director and CEO. Dr Tang has a Ph.D. in Chemical Engineering and was selected as National Distinguished Expert in China's Thousand Talents Plan in 2012.

GRDG Sciences LLC is a natural products discovery drug research company formed in Florida, USA by Mr Thompson, a natural products scientist. GRDG Sciences works with multiple global institutions such as Charles River. Holista CollTech Ltd is a research-driven biotech company that resulted from the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd. It is dedicated to delivering first-class natural ingredients and wellness products (www.holista.com).

About Singapore eDevelopment Limited

Incorporated on 9 September 2009, and listed on the Singapore Exchange Catalist (SGX:40V) in July 2010 (SP: SGE; SINE), Singapore eDevelopment is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) Information Technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg.

Issued on behalf of the Company:

WeR1 Consultants Pte Ltd

Mr Ian Lau

E: ianlau@wer1.net

T: +65 6737 4844

Singapore 048693

Topic: General Announcement

Sectors: Investors/Exchanges, Daily Finance, BioTech, HealthCare, Alternatives

www.acnnewswire.com

From the Asia Corporate News Network

Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Press Information


Published by
ACN Newswire
+65 6304 8926
e-mail
www.acnnewswire.com



# 633 Words
Related Articles
More From The Author
Singapore eDevelopment Bio-Med Subsidiary Initiates Research [..]
SINGAPORE, May 22, 2017 - (ACN Newswire) - Singapore eDevelopment Ltd ("SeD"; has, through its subsidiary Global BioLife [..]
Wintermar Offshore (WINS.JK) Shareholders approve Placement [..]
JAKARTA, INDONESIA - (ACN Newswire) - Wintermar Offshore Marine (WINS) Shareholders have approved the proposal to issue 400 [..]
Environment benefits from large middle class in [..]
A large middle class in Thailand and Indonesia is demanding more environmental protection; something not happening in other developing [..]
Printed 'coffee rings' avoided with nanofibers
Cellulose nanofibers can help particles in ink and printed electronics disperse evenly, rather than spread apart like dried coffee [..]
Indonesian National Agency of Search and Relief [..]
JAKARTA, May 18, 2017 - (ACN Newswire) - The Indonesian National Agency of Search and Relief (NASR, formerly BASARNAS) supports [..]
 
More From Health
BioFridge Medical Refrigeration Devices Launches New Website
BioFridge is a leader in portable medical refrigeration and recently launched a new website at www.biofridge.com. The company’s products [..]
Advanced Wound Care Market Size & Forecast [..]
A research study titled, “Advanced Wound Care Market by Product and Application - Global Industry Analysis and Forecast To [..]
MyMedis.in Creates a New Paradigm in the [..]
MyMedis.In is a patient-centric portal designed to store a copy of your medical records in your medical wallet. The MyMedis.In [..]
Cannabis revolution brings unintended advancements
With the acceleration of technology and it's ever-growing, widespread use, the cannabis industry is not isolate from this societal [..]
World Diabetes Day: Combating diabetic retinopathy in [..]
News release Preventing the preventable: Combating diabetic retinopathy in at risk women November 14, 2017 - report from Los [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.